Content area
Full Text
Bristol-Myers Squibb’s Opdivo is currently the only immuno-oncology treatment approved to treat kidney cancer-but yet another pair of rivals is now moving in to threaten that status.
Merck’s Keytruda, in tandem with Eisai’s Lenvima, has nabbed the FDA’s breakthrough therapy designation as a potential treatment for patients with advanced and/or metastatic renal cell carcinoma, setting the partners up for a sped-up trip down the regulatory pathway.
The designation follows “impressive” data from the duo, which, in a phase 1b/2...